McGill joins Moderna’s mRNA Access program

McGill University has announced that it has joined Moderna’s mRNA Access program. The program focuses on facilitating collaborative research and preclinical development to accelerate innovation on new vaccines and medicines that address existing and emerging diseases. Researchers will have access to an “inside track” that will allow them to prototype and develop vaccine candidates using Moderna’s antigen design capabilities, shortening the development path for potential treatments. “[J]oining this platform will help us develop vaccines that will protect human health everywhere on the planet,” said McGill Vice-Principal, Research & Innovation Martha Crago. The university is reportedly the first in Canada to join the program. McGill Note: Archived stories may contain dead links or be missing source links.